Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Stoke Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
STOK
Nasdaq
8731
https://www.stoketherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Stoke Therapeutics Inc
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
- May 8th, 2024 1:04 am
Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations
- May 7th, 2024 10:53 am
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
- May 6th, 2024 12:05 pm
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
- May 6th, 2024 11:00 am
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
- Apr 29th, 2024 2:00 pm
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
- Apr 29th, 2024 12:00 pm
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
- Apr 25th, 2024 2:01 pm
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
- Apr 17th, 2024 12:00 pm
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 4th, 2024 8:30 pm
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
- Mar 28th, 2024 3:40 am
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
- Mar 27th, 2024 12:50 pm
Stoke Therapeutics Announces Proposed Public Offering
- Mar 26th, 2024 8:07 pm
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
- Mar 26th, 2024 3:20 pm
Stoke shares surge on updated results for Dravet drug
- Mar 26th, 2024 11:49 am
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
- Mar 25th, 2024 9:10 pm
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
- Mar 25th, 2024 8:01 pm
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 25th, 2024 8:01 pm
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
- Feb 29th, 2024 1:50 pm
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
- Feb 28th, 2024 3:00 pm
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
- Feb 26th, 2024 3:00 pm
Scroll